ERBB2 and breast cancer: BC is a heterogeneous disease; it consists of tumors expressing estrogen receptor (ER) and/or HER2, as well as tumors negative for ER, progesterone receptor (PR), and HER2 expression (triple negative/TN), with approximately 75% of cases being ER-positive (ER + ve) [3,4,5].